Peloton Wealth Strategists’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.08M Buy
9,140
+100
+1% +$46.6K 1.65% 20
2025
Q4
$4.1M Buy
9,040
+1,165
+15% +$502K 1.59% 22
2025
Q3
$3.08M Sell
7,875
-275
-3% -$115K 1.21% 29
2025
Q2
$3.63M Buy
8,150
+196
+2% +$90.3K 1.46% 24
2025
Q1
$3.86M Buy
7,954
+1,920
+32% +$895K 1.61% 21
2024
Q4
$2.43M Buy
6,034
+3,859
+177% +$1.79M 0.98% 37
2024
Q3
$1.01M Buy
2,175
+1,600
+278% +$769K 0.4% 67
2024
Q2
$270K Buy
+575
New +$250K 0.11% 89

Other funds holding VRTX

Peloton Wealth Strategists's VRTX Position: Q1 2026 in Review

Peloton Wealth Strategists increased its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, buying an estimated $46.6K and bringing the position to 9,140 shares worth $4.08M. The position accounts for 1.65% of the portfolio, ranked #20.

Peloton Wealth Strategists first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.1M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Peloton Wealth Strategists held 9,140 shares of Vertex Pharmaceuticals worth $4.08M as of Q1 2026.
  • Peloton Wealth Strategists bought 100 Vertex Pharmaceuticals shares in Q1 2026, an estimated $46.6K.
  • Vertex Pharmaceuticals made up 1.65% of Peloton Wealth Strategists's portfolio in Q1 2026, its #20 holding.
  • Peloton Wealth Strategists first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Peloton Wealth Strategists's Vertex Pharmaceuticals position peaked at $4.1M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Peloton Wealth Strategists's 13F filing for Q1 2026, filed 14 May 2026.